8.96
2.17%
0.19
Dopo l'orario di chiusura:
8.85
-0.11
-1.23%
Precedente Chiudi:
$8.77
Aprire:
$8.79
Volume 24 ore:
842.18K
Relative Volume:
0.34
Capitalizzazione di mercato:
$469.52M
Reddito:
$1.02B
Utile/perdita netta:
$-757.20M
Rapporto P/E:
-0.7417
EPS:
-12.08
Flusso di cassa netto:
$-257.90M
1 W Prestazione:
-3.97%
1M Prestazione:
-4.17%
6M Prestazione:
+130.33%
1 anno Prestazione:
+270.25%
Emergent Biosolutions Inc Stock (EBS) Company Profile
Nome
Emergent Biosolutions Inc
Settore
Telefono
240-631-3200
Indirizzo
400 PROFESSIONAL DR, SUITE 400, GAITHERSBURG, MD
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-04-10 | Aggiornamento | The Benchmark Company | Hold → Buy |
2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
2022-11-10 | Downgrade | The Benchmark Company | Buy → Hold |
2022-04-29 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2022-01-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
2021-11-08 | Downgrade | The Benchmark Company | Buy → Hold |
2021-05-05 | Downgrade | Argus | Buy → Hold |
2021-04-07 | Iniziato | The Benchmark Company | Buy |
2021-02-24 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
2021-02-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
2021-01-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2020-09-14 | Ripresa | JP Morgan | Neutral |
2020-07-31 | Reiterato | Chardan Capital Markets | Buy |
2019-09-12 | Iniziato | Guggenheim | Buy |
2019-09-04 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
2018-11-02 | Aggiornamento | Goldman | Neutral → Buy |
2018-08-03 | Reiterato | Chardan Capital Markets | Buy |
2018-06-13 | Iniziato | Argus | Buy |
2018-04-25 | Downgrade | Wells Fargo | Outperform → Market Perform |
2018-01-24 | Iniziato | Goldman | Neutral |
2018-01-16 | Reiterato | Chardan Capital Markets | Buy |
2016-06-28 | Reiterato | Singular Research | Buy |
2016-04-15 | Iniziato | Chardan Capital Markets | Buy |
2016-03-28 | Iniziato | Singular Research | Buy |
2016-02-19 | Iniziato | Wells Fargo | Outperform |
2014-05-15 | Iniziato | Summer Street Research | Buy |
2011-05-31 | Reiterato | WBB Securities | Strong Buy |
2011-01-10 | Reiterato | Wedbush | Outperform |
2010-11-05 | Reiterato | Wedbush | Outperform |
2010-08-18 | Aggiornamento | WBB Securities | Buy → Strong Buy |
2010-08-06 | Reiterato | Caris & Company | Buy |
Mostra tutto
Emergent Biosolutions Inc Borsa (EBS) Ultime notizie
Biotech Co. Emergent Gives Interim GC Permanent Role - Law360
Emergent BioSolutions appoints new chief medical officer - Investing.com
Emergent BioSolutions (EBS) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Emergent Bio's smallpox vaccine gets US approval for mpox - AOL
Assenagon Asset Management S.A. Increases Stock Position in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way? - Simply Wall St
Zacks.com featured highlights include American Airlines, Air Canada, EmergentBioSolutions, Berry and Cracker Barrel Old Country Store - Yahoo Finance
5 Broker Liked Stocks to Keep an Eye on After Recent Analyst Upgrades - Yahoo Finance
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - GlobeNewswire Inc.
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024 - The Manila Times
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference - The Bakersfield Californian
Emergent BioSolutions (NYSE:EBS) Shares Up 3.2%Here's What Happened - MarketBeat
Biopharma Layoffs Roundup - Contract Pharma
Zacks.com featured highlights include Grupo Supervielle, Emergent BioSolutions and Innodata - Yahoo Finance
3 Stocks Poised for Better Returns With New Analyst Coverage - Yahoo Finance
Emergent BioSolutions Inc. (NYSE:EBS) Short Interest Up 84.1% in September - MarketBeat
Emergent BioSolutions Inc. (NYSE:EBS) Shares Sold by Dimensional Fund Advisors LP - MarketBeat
Emergent BioSolutions Inc. (EBS): A Standout Among Best Performing Cheap Stocks in 2024 - Insider Monkey
Emergent BioSolutions Inc (EBS) Q2 2024 Earnings Call Highlights: Navigating Challenges and Seizing Opportunities - GuruFocus.com
Smallpox Treatment Market to Experience Holistic Expansion - openPR
Emergent BioSolutions Inc (EBS) Q2 2024 Earnings Call Highlights: Navigating Challenges and ... - Yahoo Finance
Emergent BioSolutions Inc (EBS) Q2 2024 Earnings Call Highlights: Navigating Challenges and ... By GuruFocus - Investing.com Canada
Emergent to donate 20,000 Narcan doses to fight opioid overdoses, CEO says - Yahoo Finance
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic - The Manila Times
Emergent BioSolutions Inc. (NYSE:EBS) Shares Sold by AQR Capital Management LLC - MarketBeat
12 Best Performing Cheap Stocks in 2024 - Insider Monkey
Lipid Nanoparticles Market Research 2024 - GlobeNewswire Inc.
Emergent BioSolutions (STU:ER4) EV-to-EBITDA : -3.33 (As of Oct. 06, 2024) - GuruFocus.com
Emergent BioSolutions (STU:ER4) Profitability Rank : 7 (As of Jun. 2024) - GuruFocus.com
Emergent BioSolutions (STU:ER4) Free Cash Flow per Share : €0.69 (TTM As of Jun. 2024) - GuruFocus.com
Renaissance Technologies LLC Trims Position in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
Squarepoint Ops LLC Buys Shares of 231,014 Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
Emergent BioSolutions grants CFO equity award By Investing.com - Investing.com Australia
Emergent BioSolutions grants CFO equity award - Investing.com India
Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario - citybiz
Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario (EBS) - Seeking Alpha
Emergent BioSolutions Grants CFO Stock for Contributions - TipRanks
Marshall Wace LLP Has $3.70 Million Stake in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
Emergent BioSolutions secures $100 million credit facility By Investing.com - Investing.com South Africa
What's Going On With Emergent BioSolutions Stock Wednesday? - Benzinga
Emergent BioSolutions Closes $100 Million Financing - citybiz
Emergent Biosolutions Secures Loan, Bolsters Growth Strategy - TipRanks
Emergent BioSolutions secures $100 million credit facility - Investing.com
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility - The Manila Times
Emergent BioSolutions Inc. Announces Closing of $100 Million Asset-Backed Loan Facility - Marketscreener.com
Rhumbline Advisers Sells 69,920 Shares of Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
Emergent Bio gains after U.S. govt. order for smallpox therapy - MSN
Reviewing Pulmatrix (NASDAQ:PULM) & Emergent BioSolutions (NYSE:EBS) - Defense World
Emergent Biosolutions lays off 300 people - MSN
U.S. secures additional smallpox treatments for $67.4 million - Investing.com
Emergent Bio stock gains after U.S. govt. order (NYSE:EBS) - Seeking Alpha
Emergent Biosolutions Inc Azioni (EBS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):